Product Information

CAS No.	572924-54-0
Product Name	Ridaforolimus

Health Hazard

Environmental Hazard

Signal Word:Warning

HCode:H361-H373-H400

PCode:P203-P260-P273-P280-P318-P319-P391-P405-P501

Studies related to this compound and its mechanism of action

A role for maintenance therapy in managing sarcoma.

Cancer treatment reviews • Vol. 38, Issue 5 • 2012

PMID: 21843915 DOI: 10.1016/j.ctrv.2011.07.003

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.

Molecular cancer therapeutics • Vol. 10, Issue 6 • 2011

PMID: 21482695 DOI: 10.1158/1535-7163.MCT-10-0792

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 26, Issue 3 • 2008

PMID: 18202410 DOI: 10.1200/JCO.2007.12.0345

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 14, Issue 9 • 2008

PMID: 18451242 DOI: 10.1158/1078-0432.CCR-07-1372

Ridaforolimus

CAS No.	572924-54-0
MDL No.	N/A
MF	C₅₃H₈₄NO₁₄P
MW	990.20
InChI Key	BUROJSBIWGDYCN-GAUTUEMISA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	572924-54-0
Product Name	Ridaforolimus

Health Hazard

Environmental Hazard

Signal Word:Warning

HCode:H361-H373-H400

PCode:P203-P260-P273-P280-P318-P319-P391-P405-P501

Ridaforolimus

Pricing & Availability

Product Information

Safety Information

Properties

Ridaforolimus

Pricing & Availability

Product Information

Safety Information

Properties

Documentation

Ridaforolimus

Pricing & Availability

Product Information

Safety Information

Properties

Related Articles

A role for maintenance therapy in managing sarcoma.

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.

Similar Products

Everolimus

Rapamycin (GMP)

Biolimus A9

Laporolimus

Ridaforolimus

Pricing & Availability

Product Information

Safety Information

Properties

Related Articles

A role for maintenance therapy in managing sarcoma.

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.

Similar Products

Everolimus

Rapamycin (GMP)

Biolimus A9

Laporolimus

Documentation